Clinical trial holds delay therapies getting to market and may be on the rise in oncology. But there's a lot the public doesn't know about how often these holds happen and why.
The factor D inhibitor danicopan has been approved for use in Europe for patients with paroxysmal nocturnal hemoglobinuria with residual hemolytic anemia on standard therapy.
The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the.